Prognostic gene expression signature for high-grade serous ovarian cancer
Some women with High Grade Serous Ovarian Cancer (HGSOC) do better than others. There is an advantage in knowing which patients will have a better survival in order to personalise the medical therapy provided.
This retrospective survey looked at the gene expression in tissue samples from 3769 patients and compared the findings with overall survival.
A genetic signature of poor survival was determined with 66 different genes marking the site. The severity of the disease is directly related to this, with increased post 5 years survival for women who did not have the typical gene signature.
All women in this group received the same standard therapy with surgery and chemo. Early gene sequencing is appropriate to better assess prognosis and appropriate treatment.
No comments:
Post a Comment